Immunome
Clinical-stage oncology company focused on discovery and development of targeted cancer therapies, with core programs in antibody-drug conjugates (ADCs), radioligand therapies (RLTs), and a small-molecule gamma-secretase inhibitor. The organization conducts preclinical optimization, IND-enabling studies, and multi-part clinical trials (Phase 1 through global Phase 3), and has capabilities in CMC and drug-linker process development.
Industries
Nr. of Employees
medium (51-250)
Patents
Products
Varegacestat (gamma-secretase inhibitor)
Investigational once-daily oral gamma-secretase inhibitor being developed for progressing desmoid tumors; evaluated in a multi-part Phase 2/3 randomized, double-blind, placebo-controlled trial (RINGSIDE).
IM-1021 (ROR1-targeted antibody–drug conjugate)
ROR1-targeted ADC optimized for internalization and ADC-mediated killing using a cleavable linker and a camptothecin-derivative payload; completed preclinical efficacy studies and entered Phase 1 clinical evaluation.
IM-3050 (FAP-targeted radioligand therapy)
Radioligand therapy designed to deliver 177Lu to fibroblast activation protein (FAP)-expressing cancer-associated fibroblasts using a FAP-specific ligand, chelator, linker and albumin-binding domain; optimized for affinity, radiostability, tumor retention and biodistribution; advanced to Phase 1 clinical trial initiation.
Preclinical ADC candidates (IM-1617, IM-1340, IM-1335)
Preclinical ADC programs targeting undisclosed or underexplored receptors with demonstrated single-dose regressions in multiple solid tumor models and non-human primate toxicology consistent with TOP1 payload class effects.
IM-3050
IM-3050 is a FAP-targeted radioligand therapy that received IND clearance in Q1 2025.
IM-1021
IM-1021 is a ROR1-targeted antibody-drug conjugate currently in a Phase 1 clinical trial.
Varegacestat (gamma-secretase inhibitor)
Investigational once-daily oral gamma-secretase inhibitor being developed for progressing desmoid tumors; evaluated in a multi-part Phase 2/3 randomized, double-blind, placebo-controlled trial (RINGSIDE).
IM-1021 (ROR1-targeted antibody–drug conjugate)
ROR1-targeted ADC optimized for internalization and ADC-mediated killing using a cleavable linker and a camptothecin-derivative payload; completed preclinical efficacy studies and entered Phase 1 clinical evaluation.
IM-3050 (FAP-targeted radioligand therapy)
Radioligand therapy designed to deliver 177Lu to fibroblast activation protein (FAP)-expressing cancer-associated fibroblasts using a FAP-specific ligand, chelator, linker and albumin-binding domain; optimized for affinity, radiostability, tumor retention and biodistribution; advanced to Phase 1 clinical trial initiation.
Preclinical ADC candidates (IM-1617, IM-1340, IM-1335)
Preclinical ADC programs targeting undisclosed or underexplored receptors with demonstrated single-dose regressions in multiple solid tumor models and non-human primate toxicology consistent with TOP1 payload class effects.
IM-3050
IM-3050 is a FAP-targeted radioligand therapy that received IND clearance in Q1 2025.
IM-1021
IM-1021 is a ROR1-targeted antibody-drug conjugate currently in a Phase 1 clinical trial.
Expertise Areas
- Antibody–drug conjugate development
- Radioligand therapy development
- Clinical trial management and design
- Preclinical efficacy and toxicology
Key Technologies
- Antibody–drug conjugates (ADC)
- Radioligand therapy (RLT)
- TOP1-class payload chemistry
- Camptothecin-derivative payloads
News & Updates
Conference presentations and posters reporting clinical and preclinical data, including RINGSIDE trial materials and ADC/RLT program posters.
Regulatory IND clearance received for a FAP-targeted radioligand program in Q1 2025 and subsequent Phase 1 clinical trial initiation (first clinical site initiated March 2026).
Company announced positive top-line results from the Phase 3 RINGSIDE trial of a gamma-secretase inhibitor in desmoid tumors (press release referenced).
Conference presentations and posters reporting clinical and preclinical data, including RINGSIDE trial materials and ADC/RLT program posters.
Regulatory IND clearance received for a FAP-targeted radioligand program in Q1 2025 and subsequent Phase 1 clinical trial initiation (first clinical site initiated March 2026).
Company announced positive top-line results from the Phase 3 RINGSIDE trial of a gamma-secretase inhibitor in desmoid tumors (press release referenced).